Celldex Therapeutics

Historical price data

Celldex Therapeutics is a biopharmaceutical company committed to developing novel, targeted therapeutics for devastating diseases, with a primary focus in oncology and inflammatory conditions. Its strategy leverages proprietary antibody platforms to create precision medicines that engage the immune system. Key achievements include advancing barzolvolimab (CDX-0159) into late-stage clinical trials for chronic urticaria and generating compelling clinical data across its pipeline. The company's direction is centered on progressing its lead assets through pivotal studies while exploring their potential in additional indications.

Proprietary antibody generation platforms for developing monoclonal and bispecific antibodies, including antibody-drug conjugate (ADC) capabilities, focused on targeting specific cell surface receptors like KIT and CD40.

66 drugs in pipeline, 5 in Phase 3

Total raised: $200M

Celldex faces competition from established biologics like omalizumab (Xolair) and novel agents in late-stage development for chronic urticaria. In oncology, it competes in crowded fields like CD40 agonism and bispecific antibodies. Its differentiation lies in barzolvolimab's unique mechanism of action targeting the KIT receptor on mast cells.